ArriVent BioPharma, Inc.(AVBP)

Biotechnology · Newtown Square, PA

$28.46+0.19 (+0.67%)

Delayed quote: Oct 5, 2026, 4:00 PM EDT

PS Ratio: N/A

Basis: FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.

The P/S ratio is N/A as of 2026-10-06T13:35:38.975Z.

Stored calculation inputs

Calculation as of: 2026-10-06T13:35:38.975Z.

Quote observation: 2026-10-05T20:00:01.000Z. Amounts in USD. The price header may show a later quote.

Quote market capitalization: 1,325,522,508
TTM revenue · period ending 2026-06-30: 0

FMP input reference: 533c4696450707580a389d0c8167e09da333cd728c1767827588ef029f48caf5

P/E Ratio|Gross Margin|Revenue Growth|All Metrics

Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.

AVBP PS Ratio Metrics

PS RATIO

N/A

AVBP Competitors' PS Ratio

AVBP

ArriVent BioPharma, Inc.

Current

Market Cap

$1.33B

PS Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

KARD

Kardigan, Inc.

vs AVBP

Market Cap

$1.34B

PS Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

DRTS

Alpha Tau Medical Ltd

vs AVBP

Market Cap

$1.35B

PS Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

INBX

Inhibrx Biosciences Inc.

vs AVBP

Market Cap

$1.38B

PS Ratio

N/A

TTM Avg

865.07

3Y Avg

1036.91

5Y Avg

726.94

DMRA

Damora Therapeutics, Inc.

vs AVBP

Market Cap

$1.24B

PS Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

COAG

Hemab Therapeutics Holdings, Inc. Common Stock

vs AVBP

Market Cap

$1.42B

PS Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

INNV

Innovage Holding Corp.

vs AVBP

Market Cap

$1.23B

PS Ratio

1.24

TTM Avg

1.18

3Y Avg

0.95

5Y Avg

1.06

CRON

Cronos Group Inc.

vs AVBP

Market Cap

$1.22B

PS Ratio

5.42

TTM Avg

6.20

3Y Avg

7.49

5Y Avg

10.16

KLRA

Kailera Therapeutics, Inc.

vs AVBP

Market Cap

$1.43B

PS Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

AVLN

Avalyn Pharma Inc. Common Stock

vs AVBP

Market Cap

$1.20B

PS Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

NAME	MARKET CAP	PS RATIO	TTM	3Y	5Y
ArriVent BioPharma, Inc. (AVBP)	$1.33B	N/A	N/A	N/A	N/A
Kardigan, Inc. (KARD)vs ›	$1.34B	N/A	N/A	N/A	N/A
Alpha Tau Medical Ltd (DRTS)vs ›	$1.35B	N/A	N/A	N/A	N/A
Inhibrx Biosciences Inc. (INBX)vs ›	$1.38B	N/A	865.07	1036.91	726.94
Damora Therapeutics, Inc. (DMRA)vs ›	$1.24B	N/A	N/A	N/A	N/A
Hemab Therapeutics Holdings, Inc. Common Stock (COAG)vs ›	$1.42B	N/A	N/A	N/A	N/A
Innovage Holding Corp. (INNV)vs ›	$1.23B	1.24	1.18	0.95	1.06
Cronos Group Inc. (CRON)vs ›	$1.22B	5.42	6.20	7.49	10.16
Kailera Therapeutics, Inc. (KLRA)vs ›	$1.43B	N/A	N/A	N/A	N/A
Avalyn Pharma Inc. Common Stock (AVLN)vs ›	$1.20B	N/A	N/A	N/A	N/A

How this was calculated

Trailing-12-month revenue adds these four fiscal quarters. Amounts are in USD, rounded only to whole currency units.

Revenue calculation and filing references
Fiscal period	Revenue	Source
Q3 FY2025Period ended 2025-09-30	$0	Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2025-11-10
Q4 FY2025Period ended 2025-12-31	$0

PS Ratio Formula & Definition

PS Ratio = Market Cap / Revenue (TTM)

The price-to-sales ratio compares market capitalization to trailing revenue. It is useful for valuing companies with little or no earnings.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

About ArriVent BioPharma, Inc.

ArriVent BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers. The company’s lead development candidate is firmonertinib, a tyrosine kinase inhibitor that is being evaluated in multiple clinical trials across a range of epidermal growth factor receptor mutations (EGFRm) in non-small cell lung cancer (NSCLC), including a Phase 3 clinical trial for treatment of patients with advanced or metastatic EGFRm NSCLC with exon 20 insertion mutations, as well as Phase 1b clinical trials to treat NSCLC patients with activating EGFRm, including P-loop and-alpha-c-helix compressing (PACC) mutations, and classical EGFRm NSCLC patients. It is also developing ARR-217, an antibody drug conjugate (ADC) for the treatment of gastrointestinal cancers; and ARR-002, ARR-421, and ARR-173 for solid tumors. The company has strategic collaborations with Aarvik Therapeutics Inc., Shanghai Allist Pharmaceuticals Co., Ltd., Beijing InnoCare Pharma Tech Co., Ltd., Jiangsu Alphamab Biopharmaceuticals Co., Ltd., and Lepu Biopharma Co. Ltd. ArriVent BioPharma, Inc. was incorporated in 2021 and is based in Newtown Square, Pennsylvania.

Newtown Square, PA

77 employees

arrivent.com

Healthcare / Biotechnology